Companies Registration Office

Week of 2026-W16

Irish Corporate Affairs Weekly | Business Post

Irish Corporate Affairs Weekly

CRO Company & Business Formations, Financial Filings & Director Networks — Week of 14–20 April 2026

Source: CRO | Period: 2026-04-14 to 2026-04-20

Weekly | 14–20 April 2026

0 Companies Active in the CRO, €4.3bn in Pharma Revenue, and a €1.4m Wealth Management Lawsuit — Irish Corporate Affairs This Week

Ireland's company registry was busy in the most recent available period, with 0 companies showing activity in the CRO and 0 new business names registered — a snapshot of an economy where sole traders, tech startups, and multinational subsidiaries all file in the same queue. The headline financial story is Astellas Pharma Co. Limited's consolidated accounts, which reveal €4.3 billion in revenue for FY2025, driven by a 17.9% surge in oncology sales to €2.16 billion — a figure that underscores Ireland's role as a critical node in global pharmaceutical supply chains. Meanwhile, a €1.4 million equity dispute at Dublin wealth manager BCWM Scope Limited has landed in the courts, and a Kerry hotel company is quietly generating €17 million in annual revenue with €8.9 million cash in the bank.

Companies with CRO Activity

New Business Names Registered

Financial Reports Filed

€4.3bn

Astellas Pharma Revenue (FY2025)

111

High Court Judgments (2026 YTD)

By the Numbers

Metric	Value	Signal
Companies with CRO activity (latest period)	0	Steady
New business names registered	0	Active
Financial reports filed (Jan–Feb 2026)	0	Normal
Consolidated financial statements filed	856	High
Companies entering liquidation (period)	2	Watch
Astellas Pharma oncology revenue growth	+17.9%	Strong
Residential property avg price (2026 YTD)	€370,360	Elevated
High Court judgments delivered (2026 YTD)	111	Active

Business Post AI Pick: The Pharma Filing That Matters The consolidated accounts of Astellas Pharma Co. Limited — filed via its Dutch parent Astellas B.V. Leiden — reveal a company navigating the new Pillar Two global minimum tax regime. Ireland's two Astellas entities face a combined estimated top-up tax of €27.9 million under the OECD's 15% minimum rate. That's the price of Ireland's pharmaceutical success story: as profits grow, the tax arbitrage that made Ireland attractive narrows. The 2026 accounts will be the real test of whether the effective rate holds.

Pattern of the Week: Sole Traders Going Digital Among the 0 new business names registered in the most recent period, a striking cluster of digital and tech-adjacent names stands out: Crettyard Digital (computer programming, Laois), MediTap and TapPass (both computer programming, Tralee, Kerry — same address), and Empress Digital Solutions (computer consultancy, Dublin 15). The same Tralee address for MediTap and TapPass suggests a single founder building a dual-product tech business from Kerry — a pattern worth watching as regional tech hubs mature outside Dublin.

The CRO's most recent available data — companies active through late February 2026, business names through mid-April 2026, and financial reports through end-February 2026 — paints a picture of an Irish economy in motion. The most striking pattern this period is the dominance of pharma and automotive consolidated filings, with 856 consolidated financial statements submitted in the two-month window. These are the accounts that matter: they show group-level revenues, cross-border royalty flows, and the first real-world impact of the OECD Pillar Two minimum tax on Ireland's multinational base.

Financial Performance: Notable Filings This Period

The following companies filed the most significant financial statements in the period, ranked by revenue. These are the filings that tell the real story of Irish corporate activity — not just who registered, but who is generating value.

Company	Revenue	Profit / (Loss)	Employees	Notable
Astellas Pharma Co. Ltd View	€4.298bn	—	—	Oncology +17.9%
Realmside Limited View	€17.34m	€4.11m	140	Cash €8.88m
Nuvo Pharmaceuticals (Ireland) DAC View	US$14.95m	Net liab. US$12.4m	3	Going concern
Tony Roche Car Sales Ltd View	—	—	—	Consolidated FY2025
Trinity Motors Mazda Ltd View	—	—	—	Consolidated FY2025
Trinity JLR Ltd View	—	—	—	Consolidated FY2025
Conference Partners International Ltd View	—	—	—	Consolidated FY2025
Roadcare Works Ltd View	—	€128,863	16	Net assets €1.37m

Standout: Realmside Limited — The Quiet Hotel Performer Realmside Limited, a Kerry-based hotel company owned by Realmside Holdings Limited, filed accounts showing €17.34m in revenue for FY2025 — down marginally from €17.76m in FY2024, but with profit of €4.11m and cash at bank surging from €5.99m to €8.88m. That's a 48% increase in cash reserves in a single year, achieved while repaying €1.7m in loans. With 140 employees and €33m in long-term debt, this is a company that is deleveraging steadily while building a cash cushion. The question for 2026: does the cash pile fund a capital investment, or is it being held for a refinancing event?

Stress Signal: Nuvo Pharmaceuticals — US$87m Owed to Parent Nuvo Pharmaceuticals (Ireland) DAC, a Dublin-based pharma DAC owned by Apotex (Canada), reported net liabilities of US$12.4m at 31 March 2025. The company owes US$87.6m to its parent group — a figure that jumped from US$29.4m in the prior year, driven by a US$62m acquisition of Provigil and Nuvigil IP rights from Teva. Directors rely on a letter of support from Apotex to maintain going concern status. Revenue of US$14.95m over 15 months is real, but the balance sheet is entirely dependent on parent goodwill. Watch for the 2026 accounts to see if the IP acquisition generates the royalty uplift that justifies the debt.

Sector Breakdown: Business Names Registered This Period

The business names register — Ireland's register of sole traders and partnerships — reveals the texture of the micro-economy. The dominant sectors in the most recent batch reflect both structural trends (health, beauty, construction) and emerging patterns (digital services, EV, food).

Hairdressing & Beauty (9602)

Computer Programming (6201)

Other Human Health (8690)

Construction & Building (4120)

Restaurants & Food Service (5610)

Sale of Motor Vehicles (4511)

Engineering Consultancy (7112)

Photographic Activities (7420)

Jewellery Manufacture (3212)

Tour Operator Activities (7912)

Explore All Companies →

View All Financial Reports →

The CRO data alone tells you who registered and who filed. The connections — between a company's filings and its court appearances, between a director's network and a news story, between a business name and a property transaction — are where the real intelligence lies. This week, three themes emerge from the cross-index data: the Pillar Two tax reckoning for Ireland's pharma multinationals, a wealth management firm under legal siege, and a Chinese-backed developer reshaping Limerick's housing landscape.

Pharma Ireland and the Pillar Two Reckoning Astellas Pharma Co. Limited filed consolidated accounts showing €4.298bn in revenue for FY2025 — a 5.5% increase on FY2024's €4.07bn. The oncology division drove the growth, up 17.9% to €2.16bn, while urology declined 19.6% to €770m. But the headline number that matters for Ireland is the Pillar Two top-up tax: €8m for Astellas Pharma Europe Ltd (UK) and €19.9m for Astellas Ireland Co. Ltd — a combined €27.9m in new tax arising from the OECD's 15% global minimum. Ireland's pharmaceutical sector, which has long benefited from the 12.5% corporate tax rate, is now absorbing the cost of that success. The 2026 accounts will reveal whether the effective rate stabilises or continues to climb.

BCWM: The Wealth Manager in the Dock The Business Post reported on 20 April 2026 that a senior Goodbody advisor, Noreen O'Shea, has launched a €1.4m lawsuit against BCWM — alleging that managing director Brian Conroy promised her a 10% equity stake in the firm. BCWM manages €500m in assets for 1,500 clients and is valued at €14m based on €3.5m in annual recurring revenues. The CRO shows BCWM Scope Limited registered at 13 Upper Mount Street, Dublin 2, with €1m authorised capital — directors Brian Francis Conroy and Killian Conroy have been in place since the company's registration in September 2017. The holding company is Hottah Lake Limited. The lawsuit goes beyond a personal dispute: it raises questions about equity governance at Irish wealth management firms, where informal promises of ownership stakes are common but rarely documented. Watch for the case to proceed to full hearing in the coming months.

Chinese Capital, Irish Housing: The Limerick Connection The Business Post reported on 20 April 2026 that Siec Group, a Chinese-backed developer, has secured €100m in financing from Roundtower Capital for a Limerick housing scheme. Siec Group, owned by Tie Jun Hui, has helped 183 Chinese investors channel €111m into Irish housing through the Immigrant Investor Program (IIP) — a government scheme that grants residency rights to non-EU investors. The connection to the property market is direct: the 2026 YTD data shows 5,685 residential transactions at an average of €370,360, with the median at €331,218. Foreign capital — whether Chinese IIP money or institutional funds — is a structural feature of Ireland's housing market, not an anomaly. The question for 2026: as the IIP winds down, does Siec Group pivot to domestic financing, or does the Limerick scheme mark the end of the Chinese IIP chapter in Irish housing?

PTSB and the Banking Consolidation Wave The Business Post's dominant story this week is the €1.62bn Bawag acquisition of PTSB, with shareholders advised to reject the deal as "derisory" — analysts at Carraighill put fair value above €4 per share versus the €2.97 offer. The government, which owns 57.5% of PTSB, has given an irrevocable undertaking to vote in favour. The CRO context: PTSB is not a new registrant, but its acquisition by an Austrian bank signals a structural shift in Irish banking — from state-supported recovery to foreign-owned consolidation. For the CRO, the practical implication is a wave of subsidiary registrations, name changes, and restructuring filings as Bawag integrates PTSB's operations. Watch for those filings in the coming quarters.

The Radar: Three Signals Worth Watching

Signal 1: The Automotive Consolidation Filing Wave Four companies in the Tony Roche / Trinity Motors group — Tony Roche Car Sales Ltd, Trinity Motors Mazda Ltd, Trinity JLR Ltd, and Trinity Motors Wicklow Ltd — all filed consolidated financial statements in the same two-week window. This is not coincidence: it's a group-level compliance exercise, likely driven by a shared auditor and a common year-end of 31 March 2025. The pattern suggests a mid-sized Irish automotive group managing its CRO obligations in bulk. Watch for the actual revenue figures when the full accounts become available — the Irish new car market contracted in 2025 as EV transition costs hit dealer margins.

Signal 2: The Micro-Business Health Economy Among the 0 new business names registered, a cluster of health and wellness micro-businesses stands out: Rooted by Dr Jas (specialist medical practice, Kerry), The Neuro Centre (human health, Offaly), MYPHYSIO & REHAB LIMERICK (physiotherapy, Limerick), and Neadu Art Therapy (health activities, Kerry). This is not a random cluster: it reflects a structural shift in Irish healthcare, where GPs and allied health professionals are incorporating as sole traders to manage liability, access tax reliefs, and build portable practices. Watch for this trend to accelerate as the HSE's capacity constraints push more patients toward private and community-based care.

Signal 3: Liquidation Watch — Two Companies Enter Formal Insolvency Two companies in the CRO's most recent data entered liquidation: Publisher Services Limited (liquidation date 29/01/2026, Fitzwilliam Place Dublin 2, media sector) and Carranore Limited (in liquidation since 09/05/2022, still active in CRO records). Publisher Services is the more recent and more notable — a media distribution company entering formal insolvency in early 2026 is consistent with the structural decline of print media distribution in Ireland. Watch for the liquidator's report to reveal the creditor list and the scale of the shortfall.

Two companies this period stand out for the depth of their financial stories: Realmside Limited, a Kerry hotel operator quietly building one of the most cash-generative balance sheets in Irish hospitality, and Nuvo Pharmaceuticals (Ireland) DAC, a Dublin pharma vehicle whose US$62m IP acquisition has created a balance sheet that is entirely dependent on parent support. Together, they illustrate the two poles of Irish corporate finance: the steady accumulator and the leveraged bet.

Realmside Limited — The Hotel That Prints Cash

Realmside Limited (CRO: 567559) is a private limited company incorporated in Ireland, registered at an address in Kerry. Its parent is Realmside Holdings Limited, also Irish-registered. The company's principal activity is hotel operations — the accounts confirm it is a single-site hotel business with 140 employees, €41m in tangible fixed assets (land, buildings, fixtures), and a 31 March year-end. Directors Padraig Sugrue, Aidan O'Sullivan, Ciara O'Sullivan, and Johnny O'Sullivan have been in place since 2015 — a family-run operation with long-term management continuity.

Metric	FY2025	FY2024	Change
Revenue	€17.34m	€17.76m	−2.4%
Profit before tax	€4.52m	€5.08m	−11.0%
Profit after tax	€4.11m	€4.81m	−14.5%
Cash at bank	€8.88m	€5.99m	+48.2%
Long-term debt	€33.10m	€35.80m	−7.5%
Staff costs	€5.28m	€4.53m	+16.6%
Employees	140	145	−3.4%
Net assets	€10.2m (est.)	—	—

Reading Between the Lines: The Cash Accumulation Story Revenue fell 2.4% and profit dropped 14.5% — but cash at bank jumped 48% to €8.88m. How? The company generated €5.79m in operating cash flow, spent only €21k on capital expenditure (a near-zero investment year), and repaid €1.7m in loans. The result: a hotel that is deliberately conserving cash, not reinvesting it. Staff costs rose 16.6% — from €4.53m to €5.28m — while headcount fell from 145 to 140. That's a €750k increase in payroll for five fewer staff, suggesting significant wage inflation in Kerry hospitality. The €33m long-term debt is the constraint: at €1.17m in annual interest, the company is paying down a legacy loan book while building a cash buffer. The question for 2026: does the cash pile fund a capital investment, or is it being held for a refinancing event?

Nuvo Pharmaceuticals (Ireland) DAC — The Leveraged IP Bet

Nuvo Pharmaceuticals (Ireland) DAC (CRO: 616049) is a designated activity company at 88 Harcourt Street, Dublin 2. It is a wholly owned subsidiary of Aralez, itself owned by Apotex (Canada), which was acquired by SK Capital Partners LP in June 2024. The company's business is licensing pharmaceutical intellectual property — it holds rights to Vimovo (pain management), Provigil (modafinil), and Nuvigil (armodafinil), the last two acquired from Teva for US$62m in December 2024.

Metric	15m to Mar 2025	FY2023	Change
Revenue (turnover)	US$14.95m	US$7.53m	+98.6%
Net profit after tax	US$7.10m	(US$1.64m)	Swing
Intangible assets	US$65.10m	US$7.36m	+785%
Cash at bank	US$559k	US$929k	−39.8%
Amounts owed to parent	US$87.59m	US$29.41m	+198%
Net liabilities	(US$12.39m)	(US$19.49m)	Improving
Employees	3	3	Flat

Why It Matters: A US$62m Bet on Sleep Drugs Nuvo acquired the Irish rights to Provigil and Nuvigil — wakefulness-promoting drugs originally developed by Cephalon and sold by Teva — for US$62m in December 2024. The acquisition was financed entirely by a promissory note from parent Apotex at 7.8% interest. The result: a company with US$65m in intangible assets, US$87.6m owed to its parent, and only US$559k in cash. Revenue nearly doubled to US$14.95m over 15 months, driven by a new US$5.5m profit-share income stream. But the balance sheet is a house of cards: if Apotex withdraws its letter of support, the company cannot meet its obligations. The 2026 accounts will reveal whether the Provigil/Nuvigil IP generates the royalty uplift that justifies the debt. Watch for the first full-year accounts under the new IP ownership structure.

Key People This Period

Name	Role	Notable Activity	Connections
Brian Francis Conroy	Director / MD	Defendant in €1.4m equity stake lawsuit by former Goodbody advisor	BCWM Scope Limited
Killian Conroy	Director	Co-director at BCWM, registered since 2017	BCWM Scope Limited
Padraig Sugrue	Director	Director of hotel company generating €8.88m cash at bank	Realmside Limited
Lisa Murphy	Director	Director of €4.3bn revenue pharma subsidiary; Pillar Two exposure €27.9m	Astellas Pharma Co. Limited
Darren Keadin	Director	Signed off on Roadcare Works accounts: 16 staff, €1.37m net assets, €128k profit	Roadcare Works Limited
Eamonn Crowley	CEO	Leading PTSB through €1.62bn Bawag acquisition; government holds 57.5% stake	PTSB/Bawag deal
Tie Jun Hui	Owner	Chinese developer securing €100m Roundtower Capital financing for Limerick housing	Siec Group Limerick

One to Watch: Realmside Limited

Realmside Limited

CRO: 567559 | Kerry, Ireland | Hotel Operations | Auditor: not disclosed (small company regime)

Metric	FY2025	FY2024
Revenue	€17.34m	€17.76m
Profit after tax	€4.11m	€4.81m
Cash at bank	€8.88m	€5.99m
Employees	140	145
Long-term debt	€33.10m	€35.80m

Realmside Limited is a Kerry-based hotel company, wholly owned by Realmside Holdings Limited. It operates a single hotel property with €41m in tangible fixed assets and a management team that has been in place since 2015. The company is not publicly traded and files under the small companies regime, meaning limited disclosure.

Why it matters: this is a company that readers would not find without this newsletter. Revenue is flat, but the cash accumulation story is remarkable — €8.88m in cash against €33m in long-term debt, with €1.7m in loan repayments made in FY2025. The O'Sullivan family management structure (Aidan, Ciara, and Johnny O'Sullivan as directors alongside Padraig Sugrue) suggests a tightly held family business that is quietly building equity. The number that matters: €5.79m in operating cash flow against €21k in capital expenditure — a company that is harvesting, not investing. The 2026 accounts will reveal whether that changes.

The number that matters: €8.88m cash at bank — 51% of annual revenue held in cash, a ratio that suggests either a major investment or a refinancing event is imminent.

The Irish Courts

The High Court delivered 111 judgments in the first quarter of 2026, a pace consistent with prior years. The most business-relevant cases this period span construction contract enforcement, competition law, corporate espionage, and mortgage disputes — a cross-section of the legal risks facing Irish companies. The Rippling v O'Brien corporate espionage case, involving allegations of trade secret theft at a US tech company's Irish operations, is the most significant for the corporate sector: it signals that Irish courts are willing to grant urgent injunctive relief in cross-border IP disputes.

Citation	Parties	Subject	Why It Matters
[2026] IEHC 195	BMC Renovation v Gael Property Investments	Construction Contracts Act adjudication	€119k judgment; 'pay now, argue later' principle confirmed
[2026] IEHC 172	ER Travel v DAA PLC	Competition case — 7 years running	Expert witness unavailability; case proceeds on existing reports
[2026] IEHC 179	Rippling v O'Brien (No. 2)	Corporate espionage / trade secrets	US tech company wins Irish injunction; cross-border IP enforcement
[2026] IEHC 189	O'Callaghan v Pepper Finance Corporation	Mortgage / finance dispute	Pepper Finance (non-bank lender) defending mortgage enforcement
[2026] IEHC 196	Bytedance v Coimisiún na Meán	TikTok regulatory challenge	Tech giant challenges Irish media regulator; landmark digital case

  Construction Watch: The 'Pay Now, Argue Later' Principle
  The High Court's decision in BMC Renovation v Gael Property Investments confirms that the Construction Contracts Act 2013 — which requires contractors to be paid adjudicated amounts immediately, with disputes resolved later — applies to corporate property investors as well as individual homeowners. The residential occupier exception does not protect companies. For the construction sector, this is significant: subcontractors and main contractors can now enforce adjudicator decisions against property investment companies without waiting for full litigation. Watch for more adjudication enforcement applications as the construction sector continues to navigate post-pandemic payment disputes.

Property Markets & Plans

The Irish residential property market recorded 5,685 transactions in the first quarter of 2026, at an average price of €370,360 and a median of €331,218. The gap between average and median — €39,142 — reflects the continued pull of high-value Dublin transactions on the national average. The top transaction in the period was €5.75m for 61 Ailesbury Road, Ballsbridge — one of Dublin's most prestigious addresses — while the maximum recorded transaction was €29.1m, suggesting significant commercial or large residential activity at the top end of the market.

Address	Price	Date	Note
61 Ailesbury Rd, Ballsbridge, Dublin 4	€5,750,000	13 Mar 2026	Premium D4 residential
48 Nutley Ave, Dublin 4	€2,750,000	19 Mar 2026	D4 residential
2 Sydenham Road, Ballsbridge, Dublin 4	€1,950,000	16 Mar 2026	Ballsbridge residential
Londolozi, Torquay Rd, Foxrock, Dublin 18	€1,780,000	19 Mar 2026	Foxrock residential
22 Daneswell Place, Glasnevin, Dublin 9	€1,310,000	12 Mar 2026	North Dublin residential

View All Transactions →

The Week Ahead

The dominant theme of this period is the collision between Ireland's multinational tax model and the new global minimum tax regime. Astellas Pharma Co. Limited's €27.9m Pillar Two top-up tax is not an isolated case — it is the first visible data point in what will become a recurring feature of Irish corporate filings as the OECD's 15% minimum rate bites into the effective tax rates of Ireland's pharmaceutical and technology multinationals. The 2026 filing season will be the real test: how many companies will report Pillar Two charges, and how large will they be? The second theme is consolidation — in banking (PTSB/Bawag), in automotive (Tony Roche/Trinity Motors group filings), and in wealth management (BCWM under legal pressure). Ireland's corporate landscape is consolidating across sectors, and the CRO filings are the first place that consolidation becomes visible.

  The Bottom Line
  Ireland's corporate success story is entering a new chapter: the era of cheap tax is giving way to the era of managed tax. The Pillar Two charges now appearing in Irish CRO filings are not a crisis — they are a structural adjustment. The companies that will thrive are those that have built genuine operational substance in Ireland, not just tax-efficient holding structures. The CRO data shows that Ireland's real economy — hotels, road maintenance, pharma manufacturing, automotive retail — is generating real profits and real employment. That's the foundation that survives any tax regime change.

What to Watch: The BCWM equity stake lawsuit will proceed to full hearing — watch for discovery orders that could reveal the governance structures of other Irish wealth management firms. The Bawag/PTSB shareholder vote will test whether minority shareholders can block a government-backed deal. And the next batch of CRO financial filings will reveal how many more Irish multinationals are absorbing Pillar Two charges — the number will be larger than €27.9m.